Onconetix (ONCO) Registration Filing summary

Company overview and business model

• Commercial-stage biotech focused on men's health and oncology, with lead products Proclarix (prostate cancer diagnostic) and ENTADFI (BPH therapy).

• Proclarix is CE-marked in the EU and licensed to Labcorp for U.S. commercialization; ENTADFI commercialization is currently paused as strategic alternatives are considered.

• Business model includes product sales, licensing, and development services, with manufacturing and distribution outsourced to third parties.

• Recent strategic shift deprioritized vaccine programs to focus on diagnostics and therapeutics for men's health.

Financial performance and metrics

• For the year ended December 31, 2023, revenue was $58,465, with a net loss of $37.4 million and an accumulated deficit of $56.8 million.

• As of March 31, 2024, cash was $4.5 million, working capital deficit was $15.1 million, and accumulated deficit was $67.9 million.

• Proteomedix (acquired in December 2023) had 2022 revenue of $392,460 and a net loss of $2.0 million; for the nine months ended September 30, 2023, revenue was $2.1 million with net income of $319,188.

• Company expects to continue incurring significant operating losses and will require additional capital to sustain operations beyond Q3 2024.

• Substantial impairments recorded on ENTADFI assets ($14.7M in 2023, $2.3M in Q1 2024) and goodwill ($5.2M in Q1 2024).

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders; any proceeds from warrant exercises will be used for general corporate and working capital purposes.

• Capital allocation priorities include commercialization of Proclarix, potential resumption or monetization of ENTADFI, and funding ongoing operations.